GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's the latest in a series of legal fights over who owns the intellectual property behind mRNA technology and whether some companies are entitled to royalties on future sales.

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.

GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to mRNA technology in Moderna's COVID-19 vaccine Spikevax and RSV shot mResvia.

A Moderna spokesperson said the company was aware of the new litigation and would defend itself against the claims

London: British drugmaker GlaxoSmithKline (GSK) sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of violating GSK's patent rights in messenger RNA

GlaxoSmithKline (GSK) has filed a patent infringement lawsuit against Moderna in Delaware, accusing the company of using its patented mRNA technology in their Spikevax COVID-19 vaccine without permission.

A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent rights in its mRNA technology used to develop its COVID-19 and RSV vaccines.

Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.